S&CO Inc. Buys New Shares in United Therapeutics Corporation (NASDAQ:UTHR)

S&CO Inc. bought a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,431 shares of the biotechnology company’s stock, valued at approximately $441,000.

Several other hedge funds have also made changes to their positions in the company. Banque Cantonale Vaudoise purchased a new stake in shares of United Therapeutics in the 1st quarter valued at approximately $321,000. GSA Capital Partners LLP purchased a new stake in shares of United Therapeutics in the 1st quarter valued at approximately $958,000. Cozad Asset Management Inc. purchased a new stake in shares of United Therapeutics in the 1st quarter valued at approximately $556,000. Meeder Asset Management Inc. lifted its position in shares of United Therapeutics by 11,855.6% in the 1st quarter. Meeder Asset Management Inc. now owns 2,152 shares of the biotechnology company’s stock valued at $663,000 after acquiring an additional 2,134 shares in the last quarter. Finally, Galvin Gaustad & Stein LLC increased its stake in United Therapeutics by 15.0% in the 1st quarter. Galvin Gaustad & Stein LLC now owns 30,488 shares of the biotechnology company’s stock valued at $9,399,000 after buying an additional 3,976 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on UTHR. HC Wainwright reiterated a “buy” rating and issued a $425.00 price objective on shares of United Therapeutics in a research note on Monday, May 5th. JPMorgan Chase & Co. lowered their target price on shares of United Therapeutics from $350.00 to $330.00 and set an “overweight” rating on the stock in a research note on Tuesday, July 8th. Morgan Stanley decreased their price target on shares of United Therapeutics from $348.00 to $328.00 and set an “equal weight” rating on the stock in a research report on Thursday, July 10th. UBS Group reduced their price objective on shares of United Therapeutics from $410.00 to $385.00 and set a “buy” rating for the company in a report on Monday, June 30th. Finally, Wall Street Zen downgraded shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, May 2nd. Four analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $383.08.

Insider Activity

In other news, EVP Paul A. Mahon sold 11,000 shares of the company’s stock in a transaction that occurred on Thursday, June 12th. The shares were sold at an average price of $279.96, for a total value of $3,079,560.00. Following the completion of the transaction, the executive vice president owned 36,781 shares in the company, valued at $10,297,208.76. This represents a 23.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Richard Giltner sold 3,036 shares of the company’s stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $289.60, for a total transaction of $879,225.60. Following the completion of the transaction, the director owned 19,384 shares of the company’s stock, valued at $5,613,606.40. This trade represents a 13.54% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 81,681 shares of company stock worth $24,628,589 in the last ninety days. Company insiders own 10.30% of the company’s stock.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $298.14 on Tuesday. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $417.82. The stock has a market cap of $13.45 billion, a PE ratio of 11.90, a PEG ratio of 6.64 and a beta of 0.53. The firm’s 50 day moving average price is $299.87 and its two-hundred day moving average price is $315.03.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.29 by $0.34. The firm had revenue of $794.40 million during the quarter, compared to analysts’ expectations of $726.82 million. United Therapeutics had a net margin of 40.44% and a return on equity of 19.33%. The business’s revenue for the quarter was up 17.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $6.17 earnings per share. As a group, sell-side analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.